Boston An independent LDT provider

Invitation to Presentation of Immunovia’s Interim Report January – September 2021

October 29, 2021

LUND (SWEDEN) – Immunovia will publish the company’s interim report for the period January 1 – September 30, 2021 on Thursday, November 11, 2021 at 16:00 CET. Investors, analysts and media are invited to a telephone conference with web presentation on the same day at 16:30 CET.

CEO Patrik Dahlen will present Immunovia and comment on the interim report followed by a Q&A session. The webcasted telephone conference will be held in English.

To participate in the telephone conference, please call:

Sweden: +46 8 505 583 52

United Kingdom: +44 333 300 92 73

United States: +1 646 722 49 57

Belgium: +32 262 005 47

Denmark: +45 787 232 51

France: +33 170 750 719

Germany: +49 692 222 391 65

Norway: +47 239 636 88

Switzerland: +41 225 805 976

Netherlands: +31 207 219 496

Link to the webcast:

Following the telephone conference, a recording will be available on Immunovia’s website (

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.

In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: The European launch plan will be communicated during the second half of 2021.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit

Press release (PDF)